EP Patent

EP3495368B1 — (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor

Assigned to Organon Pharma UK Ltd · Expires 2023-05-31 · 3y expired

What this patent protects

Patent listed against Calquence.

Drugs covered by this patent

Patent Metadata

Patent number
EP3495368B1
Jurisdiction
EP
Classification
—
Expires
2023-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Organon Pharma UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.